Gilead Accused Of Antitrust Scheme Over HIV Meds

By Adam Lidgett · October 7, 2020, 10:11 PM EDT

Gilead Sciences Inc. schemed to monopolize the market for drugs commonly used to treat HIV and forced direct buyers to overpay for the medications as a result, a new proposed class...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

KPH Healthcare Services, Inc. v. Gilead Sciences, Inc. et al

Case Number

Court

California Northern

Nature of Suit

Anti-Trust

Date Filed

October 06, 2020

Recent Articles By Adam

November 18, 2024
Medical Group Wants Justices To Review IP Safe Harbor Fight
November 01, 2024
Jury To Decide Timing Issue In Insulin Patch Trade Secret Row
October 22, 2024
Patent Office Finds Public Engagement Leader
September 23, 2024
Fed. Circ. OKs Novartis Loss In Eye Syringe Patent Feud
July 11, 2024
Senate Clears Patent Bill Aiming To Lower Drug Prices
June 07, 2024
DC Circ. Undoes Library Of Congress Win In Fair Use Fight
June 06, 2024
8th Circ. Affirms Cigna Noncompete Applies To CVS Hire
May 29, 2024
Greenberg Traurig Adds IP Atty From Eversheds Sutherland
May 20, 2024
Judge Tosses Acuitas' COVID Biotech IP Suit
April 30, 2024
FTC Continues To Target 'Junk' Drug Patents